Skip to main content

Table 6 The Cox regression model of the main adverse events

From: The safety of antithrombotic therapy in patients with cerebral microbleeds and cardiogenic cerebral embolism due to nonvalvular atrial fibrillation

Variable All-cause death CH events
Hazard Ratio 95% confidence interval P value Hazard Ratio 95% confidence interval P value
CMBs 1.467 0.532–4.044 0.458 2.349 0.945–5.840 0.066
Male gender 0.714 0.263–1.944 0.510 0.854 0.331–2.206 0.745
Smoking 1.613 1.117–2.328 0.036 1.413 0.951–2.102 0.090
Hypertension history 1.769 0.538–5.814 0.347 2.840 1.886–4.276 0.025
Diabetes history 1.252 0.453–3.459 0.665 1.251 0.470–3.327 0.654
CI history 1.819 0.615–5.380 0.279 0.633 0.174–2.301 0.488
CH history 4.178 2.336–7.472 0.026 3.028 1.524–6.017 0.038
Anticoagulant therapy 0.690 0.573–0.832 0.003 1.724 0.664–4.772 0.263
NIHSS score ≥ 5 1.613 1.372–1.896 < 0.001 2.376 1.236–4.569 0.043